Lustra and the Dual-Pathway Breakthrough: How It Works in Women and Men

Most products in this category try to pull a single lever.

They either focus on blood flow or they focus on desire and signaling in the brain. The scientific case for a dual-pathway formula is that sexual response is not a one-switch system. It is a coordinated event involving the vascular system, the central nervous system, local tissue signaling, and context-dependent arousal. Avanafil sits on the vascular side as a PDE5 inhibitor in the nitric oxide and cGMP pathway. Bremelanotide, also known as PT-141, is a melanocortin receptor agonist that acts in the brain. That makes the pairing interesting because it aims to address both the mechanical and psychological/neurobiological dimensions of sexual response. (FDA Access Data)

There is one important nuance up front. The science behind each ingredient is real and documented, but the specific finished combination should be described carefully. Avanafil has FDA-approved use in erectile dysfunction, and bremelanotide has FDA-approved use for acquired, generalized HSDD in premenopausal women. The theory behind combining them is biologically coherent, but that exact combined formula is best described as a mechanistic, dual-pathway strategy rather than something proven by large, finished-product outcome trials. (FDA Access Data)

Why a dual-pathway design matters

Sexual response usually begins with a chain of events, not a single event. A cue, thought, touch, or emotional trigger engages the brain. The brain then modulates autonomic output, neurotransmitters, and motivational circuitry. At the same time, local tissues need to become physically responsive, which involves nitric oxide release, smooth muscle relaxation, increased blood flow, engorgement, and, in women, lubrication and genital vasocongestion. In men, the same biology supports erection through increased cavernosal blood flow. In both sexes, the system works best when the brain is engaged and the tissue is capable of responding. (PubMed)

This is why one-dimensional products can feel incomplete. A purely vascular agent may improve genital blood flow, but in women especially, the link between genital response and subjective arousal can be imperfect. A 2010 review noted that discordance between physical and subjective arousal helps explain why PDE5-only strategies often have mixed efficacy in women. On the other hand, a centrally acting agent may support desire and arousal signaling but still leave the peripheral tissue side underpowered. The breakthrough idea is that a dual-pathway design tries to bring both halves of the orchestra on stage at the same time. (PubMed)

Step 1: What avanafil does

Avanafil is a selective PDE5 inhibitor. PDE5 is the enzyme that breaks down cGMP. During sexual stimulation, nitric oxide is released locally, activating guanylate cyclase and increasing cGMP. That cGMP promotes smooth muscle relaxation and greater blood flow. By inhibiting PDE5, avanafil helps preserve cGMP, so the vascular signal lasts longer and works more efficiently. The FDA labeling for avanafil explicitly states that it works within the nitric oxide and cGMP pathway and does not create sexual stimulation on its own in the absence of that upstream trigger. (FDA Access Data)

That detail matters. Avanafil is not a magic “on” button. It is more like a signal amplifier for the vascular response that follows sexual stimulation. In men, that means better support for smooth muscle relaxation in the corpus cavernosum and improved blood inflow. In women, the same type of vascular physiology is relevant to genital arousal because sexual arousal in females also involves increased pelvic blood flow, clitoral and labial engorgement, and lubrication-related changes linked to vasocongestion. (FDA Access Data)

Step 2: What PT-141 does

PT-141, or bremelanotide, works very differently. It is a melanocortin receptor agonist, and the FDA label identifies it as such. The exact clinical mechanism in women is not fully established in the labeling, but reviews of the neurobiology indicate that it likely acts through melanocortin receptors, especially MC4R, in brain regions involved in desire, motivation, and reward-related sexual behavior. One review described evidence suggesting activation of presynaptic MC4 receptors in the medial preoptic area of the hypothalamus, with downstream dopamine effects that may support sexual desire. (FDA Access Data)

That is a very different lane from PDE5 inhibition. PT-141 is not primarily about increasing blood flow to tissue. It is about modulating central desire pathways, or in plainer language, the brain circuitry that helps convert context, cues, and motivation into sexual interest and arousal readiness. In women with HSDD, clinical trials found that bremelanotide significantly improved sexual desire and reduced related distress compared with placebo, although reviews note that the overall clinical benefit is modest rather than miraculous. (PubMed)

How Lustra works step by step in women

Step 1: It addresses the brain first

For many women, arousal is not just a local increase in blood flow. Female sexual response is often more tightly linked to central processing, meaning desire, receptivity, motivation, emotional context, and attentional engagement play an outsized role. Reviews of HSDD and female sexual neurobiology describe the balance between excitatory neurotransmitters, such as dopamine, norepinephrine, oxytocin, and melanocortins, and inhibitory influences, such as serotonin and opioids. PT-141 matters here because it is aimed at the central excitatory side of that balance. (PubMed)

Step 2: It supports the peripheral response

Female arousal is also physical. Increased genital blood flow supports vasocongestion, sensitivity, and lubrication-related changes. Reviews of female sexual physiology describe this as a neurovascular event, not a vague mystery. That is where the avanafil piece becomes relevant. By supporting the nitric oxide-cGMP pathway, a PDE5 inhibitor may amplify the peripheral vascular component of female arousal. Meta-analytic evidence suggests PDE5 inhibitors can improve some aspects of female sexual dysfunction, though results across studies have been mixed and may depend on subgroup and symptom pattern. (PubMed)

Step 3: It tries to solve the “discordance” problem

One of the biggest challenges in female sexual medicine is that genital response and subjective arousal do not always move together. A woman may show measurable changes in genital blood flow without feeling mentally engaged, or may feel interested but still lack a robust physical response. That is exactly why a dual-pathway idea is scientifically compelling for women. PT-141 targets the central, subjective side. Avanafil is aimed at the peripheral, vascular side. The formula’s promise is not that one molecule does everything, but that two different mechanisms may reduce the mismatch between mind and body. (PubMed)

Step 4: Why this can feel like a breakthrough for women

Traditional sexual-health products have often been designed around male erectile physiology and then awkwardly repurposed. Bremelanotide was approved specifically for women with acquired, generalized HSDD, which is notable because it represents one of the few FDA-recognized pharmacologic approaches centered on female desire rather than only genital mechanics. When a central arousal modulator is paired with a vascular response modulator, the concept extends beyond “blood flow.” It becomes a model that acknowledges what female sexual science has been saying for years: female response is brain-plus-body, not one or the other. (FDA Access Data)

How Lustra works step by step in men

Step 1: It supports the established erection pathway

In men, the avanafil side is more straightforward because PDE5 inhibition for erectile dysfunction is already a well-established model. Sexual stimulation triggers nitric oxide release in penile tissue. Nitric oxide raises cGMP. Avanafil prevents cGMP breakdown, helping smooth muscle relax and improving blood inflow. That is the classic mechanical component of erectile support. (FDA Access Data)

Step 2: It adds a central arousal signal

What makes the male case more interesting is the PT-141 layer. Male sexual performance is not only a hydraulic problem. It is also shaped by arousal circuitry, anticipatory desire, reward signaling, and central responsiveness. Early studies of PT-141 in healthy men and in men with erectile dysfunction found dose-dependent erectile activity, and other work reported that PT-141 could improve response even in sildenafil nonresponders or when coadministered with sildenafil. That suggests melanocortin signaling can augment male sexual response from the central side, not only the local vascular side. (PubMed)

Step 3: It targets men whose issue is not purely vascular

A major limitation of treating male sexual function as a blood-flow-only issue is that some men have a meaningful central arousal component. Stress, mental fatigue, low anticipatory desire, and reduced central responsiveness can all blunt sexual function even when vascular support is present. A formula that pairs a PDE5 inhibitor with a melanocortin agonist is attractive because it can, in theory, support both the end-organ blood-flow side and the desire/activation side. (PubMed)

Step 4: Why this can feel like a breakthrough for men

For men, the breakthrough is not that PDE5 inhibition is new. It is the formula that tries to move beyond a single-lane ED model. The male data on PT-141 suggests central melanocortin activation can produce measurable erectile effects and can augment other therapies. That makes the combination scientifically notable: avanafil supports vascular execution, while PT-141 may support central initiation and amplification. Mechanistically, that is a more complete picture of male sexual response than blood flow alone. (PubMed)

Why this is scientifically different from “standard” products

The strongest scientific argument for a product like this is that it treats sexual response as a systems problem.

Not just circulation.
Not just desire.
Not just tissue.
Not just psychology.

A systems view recognizes that central and peripheral pathways constantly communicate. In women, this matters because subjective arousal and genital response are often imperfectly synchronized. In men, this matters because arousal, attention, and motivation influence the effectiveness of the vascular response. A dual-pathway approach is compelling precisely because it respects biology rather than pretending that one switch controls everything. (PubMed)

What “breakthrough” should mean here

A real breakthrough is not just stronger marketing glitter.

In this case, “breakthrough” is best used to describe the design logic:

1. one ingredient with a documented role in the nitric oxide and cGMP pathway,

2. one ingredient with documented melanocortin-based central effects,

3. relevance to both men and women, but for different physiological reasons,

4. and a formula concept that better matches how sexual response actually works. (FDA Access Data)

That does not mean every person should automatically use it. The science supports the rationale, but it does not support saying this is universally appropriate for everyone. Avanafil, for example, carries important contraindications with nitrates because of hypotension risk, and bremelanotide has its own adverse-effect profile, including nausea being common in trials. A strong educational piece should say the exciting part and the careful part in the same breath. (FDA Access Data)

Why some people may find it worth considering

The people most likely to be intrigued by this concept are those who feel that a one-dimensional approach misses part of the puzzle. Someone who has a desire but wants stronger physical responsiveness may care about the vascular side. Someone who has physical capacity but lacks central engagement may care about the melanocortin side. Someone who experiences a mismatch between mind and body may be especially interested in a formula designed around both. That is the real story here: not “everyone needs this,” but “many people have more than one pathway involved, and this design tries to reflect that biology.” (PubMed)

Bottom line

Lustra is scientifically interesting because it is built around a simple but powerful insight: sexual response is dual-pathway biology.

• Avanafil supports the nitric oxide and cGMP cascade that drives vascular responsiveness. (FDA Access Data)

• PT-141 supports central melanocortin signaling tied to desire and arousal circuitry. (FDA Access Data)

• Women may benefit from this logic because female response often depends on both subjective arousal and genital blood-flow changes, and those do not always align on their own. (PubMed)

• Men may benefit from this logic because sexual function is not only vascular; central arousal signaling can also materially influence response. (PubMed)

That is what makes the concept feel new. It is not simply “more of the same.” It is a formula built around the idea that mechanical readiness and psychological arousal are partners, not rivals. And in the science of sexual response, that is a much smarter place to begin.